Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia

Current and Emerging Treatments for Chronic Lymphocytic Leukaemia

(2010) Tadeusz Robak et al.   DRUGS

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy

(2010) L Ysebaert et al.   LEUKEMIA

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

(2009) J. C. Byrd et al.   BLOOD

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

(2009) B. F. Eichhorst et al.   BLOOD

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

(2009) Apostolia-Maria Tsimberidou et al.   CANCER

Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity

(2009) Tadeusz Robak   CURRENT MEDICINAL CHEMISTRY

Bendamustine in the treatment of chronic lymphocytic leukemia

(2009) Wolfgang Knauf   Expert Review of Anticancer Therapy

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

(2009) J E Castro et al.   LEUKEMIA

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL

(2009) Stefan Faderl et al.   LEUKEMIA RESEARCH

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

(2009) Tadeusz Robak et al.   MOLECULES

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response

(2008) O. V. Oskolkova et al.   BLOOD

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

(2008) G. Salles et al.   BLOOD

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion

(2008) Tadeusz Robak et al.   CANCER

Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

(2008) Tadeusz Robak   CURRENT CANCER DRUG TARGETS

Alemtuzumab for B-cell chronic lymphocytic leukemia

(2008) Tadeusz Robak   Expert Review of Anticancer Therapy

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2008) Kenneth A. Foon et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

(2008) J E Castro et al.   LEUKEMIA